120例扁平疣患者联合治疗的临床疗效观察

目的观察卡介菌多糖核酸、重组人干扰素α-2b凝胶联合耳部割治治疗扁平疣的疗效。方法 120例扁平疣患者随机分为三组,每组40例,第一组为卡介菌多糖核酸、重组人干扰素α-2b凝胶联合耳部割治治疗,第二组为重组人干扰素α-2b凝胶联合耳部割治治疗,第三组为卡介菌多糖核酸联合耳部割治治疗,疗程4周。结果治疗4周后第一组的总有效率65.0%,第二组总有效率37.5%,第三组的总有效率为40.0%,第一组疗效与其他两组疗效比较差异有统计学意义。结论卡介菌多糖核酸、重组人干扰素α-2b凝胶联合耳部割治治疗扁平疣取得较好的临床疗效。     

面部发疹性毳毛囊肿1例

临床资料患 患女，25岁。因前额和两侧烦部出现丘疹2年余．增多近1个月就诊。患者2年前无明显诱因前额和两侧颊部出现许多蓝黑色及正常肤色丘疹，偶有轻痒，出汗时丘疹明显增多，而在寒冷环境下略变小。曾在当地医院就诊，诊断为“汗管瘤”，未予特殊治疗。1年前曾于外院诊断为表皮囊肿，部分皮损予电离子治疗，1个月后治疗部位皮损复发。     

白癜风患者外周血CD4+CD25+调节性T细胞的检测

Objective To determine the level of peripheral CD4+CD25+ regulatory T lymphocytes in patients with vitiligo at different stages and to study its relationship with the development of vitiligo. Methods Blood samples were collected from 34 outpatients with vitiligo, including 19 cases of progressive vitiligo and 15 cases of stable vitiligo, as well as from 20 normal human controls. Flow cytometry was used to detect the levels of peripheral CD4+ and CD4+CD25+ T lymphocytes in these samples. Results Compared with the controls, the percentage of CD4+CD25+ regulatory T lymphoeytes in peripheral lymphocytes was significantly lower in patients with progressive vitiligo than those in patients with stable vitiligo and normal human con-trois [(2.43±0.30)% vs (3.49±0.39)% and (3.34±0.24)%, both P <0.05], but no significant difference was found between patients with stable vitiligo and normal human controls (P＞0.05). A significantly nega-tive correlation was observed between the percentage of CD4+CD25+ regulatory T lymphocytes and lesion area in patients with progressive vitiligo (r = -0.48, P <0.05), but not in patients with stable vitiligo (P ＞0.05). There was no significant correlation between the course of disease and the percentage of peripheral CD4+CD25+ regulatory T lymphocytes in patients with progressive vitiligo or stable vitiligo (both P ＞ 0.05). Conclusion There is an abnormal proportion of peripheral CD4+CD25+ regulatory T lymphocytes in patients with vitiligo, which may be related to the development of vitiligo.     

艾迪注射液配合放疗治疗中晚期胸部恶性肿瘤临床观察

目的观察艾迪注射液对中晚期胸部恶性肿瘤患者放疗的增效减毒作用。方法将60例中晚期胸部恶性肿瘤患者随机分为治疗组与对照组各30例，均接受直线加速器6MV-X射线连续常规分割外照射。治疗组自放疗第1日开始予以艾迪注射液50ml静滴，每日1次，至放疗结束，共6-7周。结果放疗同时静脉注射艾迪注射液的患者细胞免疫水平、有效率、KPS评分、白细胞水平均明显高于对照组。结论艾迪注射液可明显改善胸部恶性肿瘤患者放疗后的细胞免疫功能状态，提高放疗的效果，进一步提高胸部恶性肿瘤患者的生存质量，且能减轻放疗的毒副反应，对于胸部恶性肿瘤放疗有减毒增效作用。     

更昔洛韦与阿昔洛韦治疗带状疱疹116例疗效比较

阿昔洛韦治疗带状疱疹国内已有文献报道,更昔洛韦是继阿昔洛韦后开发的广谱抗DNA病毒药,是目前最新的抗疱疹病毒药。我们于2004年1月~2005年2月在住院患者中用该药治疗带状疱疹并与阿昔洛韦进行比较,现将结果报道如下。临床资料病例选择:带状疱疹病人病程≤7天,年龄17~70岁,1周内未服用或外用抗病毒药物者,排除严重肝、肾功能不全、全身衰竭、肿瘤、自身免疫性疾病患者及应用糖皮质激素或免疫抑制剂者、对阿昔洛韦或更昔洛韦过敏者及妊娠和哺乳期妇女。按入院顺序随机分为治疗组和对照组,治疗组60例,对照组56例,两组的年龄、性别、病程以…     

颅内肿瘤放疗致急性肿瘤溶解综合征1例

1病例介绍 患者，男，34岁。因反复头痛2月，加重10天就诊。体检生命体征平稳，意识清，双侧瞳孔等大，对光反射灵敏。颜面部痛觉、角膜反射及听力粗测正常。张口无偏斜，病理征未引出。血常规、肝肾功能及电解质均正常。头颅MRI：右侧额叶、右基底节区、右侧大脑脚、右侧胼胝体及左侧额叶多发占位，性质待查。胸部盆腔CT未见明显异常，腹部B超未见明显异常。     

阿维A联合复方甘草酸苷治疗脓疱性银屑病的疗效观察

目的观察阿维A联合复方甘草酸苷治疗脓疱性银屑病的疗效。方法治疗组27例,予阿维A胶囊口服联合复方甘草酸苷注射液;对照组25例,单用阿维A胶囊口服,两组均治疗8周后进行疗效比较。结果治疗组有效率85.2%,对照组有效率60.0%,治疗组显著优于对照组(P<0.05)。结论阿维A联合复方甘草酸苷治疗脓疱性银屑病显著提高疗效,同时可减轻阿维A的副作用。     

药物实验湿疹离体模型的初步应用

目的利用干扰素-γ(IFN-γ)与抗Fas单克隆抗体(AntiFasmab)诱导角质形成细胞凋亡,模拟湿疹样皮炎的部分发病机制作为离体实验模型,研究中药单体人参皂甙化合物Ⅰ、Ⅱ的可能治疗作用.方法将IFN-γ、AntiFasmab作用于体外培养角质形成细胞colo-16,用流式细胞仪、倒置显微镜、荧光显微镜观察colo-16细胞凋亡情况及单体人参皂甙化合物Ⅰ、Ⅱ对colo-16凋亡的抑制作用.结果①流式细胞仪检测IFN-γ对colo-16细胞Fas抗原的表达有明显的上调作用.②colo-16表面Fas抗原的表达与其凋亡呈正相关.③IFN-γ、AntiFasmab二者联合作用于colo-16可诱导细胞凋亡,镜下可见典型的细胞凋亡形态学特征.④单体人参皂甙化合物Ⅰ、Ⅱ对colo-16的凋亡有部分阻断作用.结论①IFN-γ对角质形成细胞Fas抗原的表达有上调作用.②IFN-γ、AntiFasmab共同作用可诱导角质形成细胞凋亡.③单体人参皂甙化合物Ⅰ、Ⅱ可抑制角质形成细胞凋亡.     

白癜风患者外周血CD4+CD25+调节性T细胞的检测

Objective To determine the level of peripheral CD4+CD25+ regulatory T lymphocytes in patients with vitiligo at different stages and to study its relationship with the development of vitiligo. Methods Blood samples were collected from 34 outpatients with vitiligo, including 19 cases of progressive vitiligo and 15 cases of stable vitiligo, as well as from 20 normal human controls. Flow cytometry was used to detect the levels of peripheral CD4+ and CD4+CD25+ T lymphocytes in these samples. Results Compared with the controls, the percentage of CD4+CD25+ regulatory T lymphoeytes in peripheral lymphocytes was significantly lower in patients with progressive vitiligo than those in patients with stable vitiligo and normal human con-trois [(2.43±0.30)% vs (3.49±0.39)% and (3.34±0.24)%, both P <0.05], but no significant difference was found between patients with stable vitiligo and normal human controls (P＞0.05). A significantly nega-tive correlation was observed between the percentage of CD4+CD25+ regulatory T lymphocytes and lesion area in patients with progressive vitiligo (r = -0.48, P <0.05), but not in patients with stable vitiligo (P ＞0.05). There was no significant correlation between the course of disease and the percentage of peripheral CD4+CD25+ regulatory T lymphocytes in patients with progressive vitiligo or stable vitiligo (both P ＞ 0.05). Conclusion There is an abnormal proportion of peripheral CD4+CD25+ regulatory T lymphocytes in patients with vitiligo, which may be related to the development of vitiligo.     

白癜风患者外周血CD4+CD25+调节性T细胞的检测

Objective To determine the level of peripheral CD4+CD25+ regulatory T lymphocytes in patients with vitiligo at different stages and to study its relationship with the development of vitiligo. Methods Blood samples were collected from 34 outpatients with vitiligo, including 19 cases of progressive vitiligo and 15 cases of stable vitiligo, as well as from 20 normal human controls. Flow cytometry was used to detect the levels of peripheral CD4+ and CD4+CD25+ T lymphocytes in these samples. Results Compared with the controls, the percentage of CD4+CD25+ regulatory T lymphoeytes in peripheral lymphocytes was significantly lower in patients with progressive vitiligo than those in patients with stable vitiligo and normal human con-trois [(2.43±0.30)% vs (3.49±0.39)% and (3.34±0.24)%, both P <0.05], but no significant difference was found between patients with stable vitiligo and normal human controls (P＞0.05). A significantly nega-tive correlation was observed between the percentage of CD4+CD25+ regulatory T lymphocytes and lesion area in patients with progressive vitiligo (r = -0.48, P <0.05), but not in patients with stable vitiligo (P ＞0.05). There was no significant correlation between the course of disease and the percentage of peripheral CD4+CD25+ regulatory T lymphocytes in patients with progressive vitiligo or stable vitiligo (both P ＞ 0.05). Conclusion There is an abnormal proportion of peripheral CD4+CD25+ regulatory T lymphocytes in patients with vitiligo, which may be related to the development of vitiligo.